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Available online 13 June 2009The prevalence of peripheral arterial disease (PAD) in the
general population varies between 7% and 21%.1,2 This is
strongly related to age, gender and the definition of PAD,
defined by the ankleebrachial index (ABI) cut-off and/or
the presence of intermittent claudication (IC). PAD is
typically asymptomatic before progressing to clinical stages
such as IC or even critical limb ischaemia.3 The ABI, as
a screening tool, has emerged as an accurate and reliable
marker of (a)symptomatic PAD and as a measure of
systemic atherosclerotic burden. The getABI study detec-
ted a PAD prevalence of 18% in the primary-care setting,
while only 2.8% of the patients were symptomatic.2
In this issue of the Journal, Ramos et al. identified the
prevalence of symptomatic and asymptomatic PAD in
a population-based, cross-sectional study including 6262
participants aged 35e79 years.4 Furthermore, they evalu-
ated the value of ABI measurement in addition to coronary
heart disease (CHD) risk estimation. PAD, defined as an
ABI< 0.9, was present in 4.5% of the study population, of
which only 0.62% presented with IC assessed by the Edin-
burgh questionnaire. Prevalence increased up to 14% in* Corresponding author. D. Poldermans, MD, Department of
Vascular Surgery, Erasmus Medical Center, ’s-Gravendijkwal 230,
room H805, 3015 CE Rotterdam, the Netherlands.
Tel.: þ31 10 7034613; fax: þ31 10 7034957.
E-mail address: d.poldermans@erasmusmc.nl (D. Poldermans).
1078-5884/$36 ª 2009 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2009.05.001patients aged 75e79 years. These findings are in line with
several previous population-based studies, demonstrating
a relation between age and prevalence of PAD. Importantly,
the vast majority of the patients were asymptomatic,
addressing the importance of PAD detection in an early
phase.1,2
Cardiovascular Risk Stratification and
Treatment
The present study evaluated the CHD risk for all partici-
pants, aged 35e74 years and free of cardiovascular disease,
using the Framingham function adapted to Spain and vali-
dated in this population. The mean 10-year CHD risk in the
subgroup of patients with ABI< 0.9 was 9.2% in men and
3.0% in women. In 16.8% of the patients with ABI< 0.9, the
10-year CHD risk was moderate to high (10%). There was
an inverse association between ABI and the 10-year CHD
risk. Combining CHD risk estimation with ABI measurement
changed the proportion of participants aged 35e74 years
with CHD risk 10% from 6.1% to 8.7%. Over the last years,
PAD has become an indicator disease for generalised
atherosclerosis. Study results reported a high prevalence of
coronary artery disease (CAD) and cerebrovascular disease
(CVD) in PAD patients.5,6 The Framingham CHD risk function
was developed to provide a 10-year risk estimate for the
development of CHD in patients free of cardiovasculard by Elsevier Ltd. All rights reserved.
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ABI< 0.9 in the screening process resulted in a considerable
increased proportion of moderate-to-high risk population
when combined with 10-year risk 10% by risk functions
using the chi-square tests.
High prevalence of multiple affected vascular beds (poly-
vascular disease) not only in patients with symptomatic PAD
but also in asymptomatic patients was reported by several
studies.2 The REACH registry indicated that in patients with
symptomatic PAD, one out of six (17%) patients have
concomitant CAD and/or CVD.6 As patients with (a)symp-
tomatic PAD have a high prevalence of polyvascular disease,
the impact of this disease in asymptomatic PAD patients may
have huge consequences as well for (1) the need for
screening, (2) preventive lifestyle modification and (3)
medical treatment. The REACH registry demonstrated that
PAD patients are generally ignored with respect to lifestyle
changes and risk factor management.6 Treatment goals
according the current guidelines include aspirin and statins
(loweintermediate risk (Lee cardiac index <2) patients:
target LDL level <100 mg dl1, high-risk (Lee cardiac index
2) patients <70 mg dl1) for patients with PAD, and, if
necessary, combined with antihypertensive drugs to achieve
a target blood pressure below 140/90 mmHg.7 In patients
with ischaemic heart disease, additional recommended
therapy consists of beta-blockers. Furthermore, in case of
diabetes mellitus and/or heart failure (left ventricular
ejection fraction<40%), treatment should be extended with
ACE-inhibitors or Angiotensin receptor blockers in case of
intolerance.8 Importantly, a recent study showed that there
is a care-gap in medical treatment between guideline
recommendations and clinical practice in PAD patients.9
Therefore, especially for patients with polyvascular disease,
medical treatment adherence according the current guide-
lines needs to be emphasised.
In conclusion, the current study demonstrated a preva-
lence of symptomatic and asymptomatic PAD that is in line
with previous studies in the primary-care setting.2 The low
prevalence of symptomatic PAD in these patients indicates
that PAD can only be comprehensively diagnosed by
systematic screening, including ABI measurement. The
additional value of ABI measurement to CHD risk estimation
outlines the impact of PAD as an indicator of atheroscle-
rotic disease, which is often not limited to one arterial
location. Therefore, screening for asymptomatic PAD in
high-risk patients needs to be part of systematic screening
for atherosclerotic disease. Development of less time-
consuming ABI measurement techniques should be sup-
ported to enlarge the applicability of ABI measurement in
the primary-care setting. Furthermore, the high prevalenceof asymptomatic PAD creates the need for optimal lifestyle
modification and medical treatment, as stated by the
current guidelines on PAD.
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